Objective: To assess the course of sexual function in epilepsy patients treated with lamotrigine.
Introduction
An increased risk for sexual and reproductive dysfunction has been well-documented in patients with epilepsy. These deficiencies have a deleterious impact in the patient's quality of life, and include diminished libido, dyspareunia, erectile dysfunction, and lack of sexual satisfaction. [1] [2] [3] In women with epilepsy, irregularities of the menstrual cycle, anovulatory cycles, and polycystic ovaries are more frequent than in the general population; 4 in men with temporal lobe epilepsy increases in the incidence of reproductive endocrine disorders, such as hypogonadism and hyperprolactinemia, have been reported. 5 Sexual dysfunction can be related to recurrent seizures, the etiology of epilepsy, and associated psychological disorders. In addition, antiepileptic drugs (AEDs) can also impair sexual and reproductive function. Thus, in some studies the use of valproic acid has been associated with the development of polycystic ovaries in women 6 and reduced testicular volume in men 7 while phenytoin, carbamazepine, and barbiturates, have been associated with erectile dysfunction and reduced libido. 8 Because of this, it has been postulated that a change of AED could improve sexual function in affected patients. However, at the present time there are no reliable data on which drugs are least likely to affect sexual function.
Lamotrigine is an extended-spectrum antiepileptic agent approved for use, in monotherapy and association therapy, for the treatment of focal and generalized epilepsies in adults and children. [9] [10] [11] Several lines of evidence suggest that, compared to some other AEDs, lamotrigine is associated with a lower risk of causing sexual dysfunction. First, some studies have shown a lower incidence of hormonal alterations and polycystic ovarian syndrome in women who took lamotrigine in comparison to women treated with valproic acid. 12 Second, lamotrigine does not induce cytochrome P-450 enzymes, a mechanism that has been related to endocrine changes leading to sexual and reproductive dysfunction. 3 And third, published case reports suggest an improvement in sexual dysfunction at least in some patients who were switched to lamotrigine. 13 The aim of this study is to assess sexual function in patients with epilepsy treated with lamotrigine.
Methods Subjects
Participants in this open, prospective, and multicentre study were 280 adults (age !18 years) with epilepsy, followed for an 8-month period at various epilepsy clinics in Spain. Included patients received lamotrigine as a first treatment for epilepsy (n = 156), or were switched to lamotrigine monotherapy after treatment with another AED failed to control seizures or were associated with intolerable adverse events (n = 124). Patients were considered uncontrolled when they had one or more seizures with impairment of consciousness after attaining steady state with an AED at the clinically recommended maintenance dosage. Excluded from the study were pregnant or breastfeeding women, patients with serious hepatic or renal disorders, patients with malignancies or untreated endocrine disorders (hypogonadism, hypothyroidism or hypopituitarism), patients with psychiatric and cardiac disorders that prevented regular sexual activity or substantially modified sexual response, patients with hypersensitivity to lamotrigine or any of its vehicles, and those who received medication that could induce modifications in sexual function in the 3 months prior to the study period or during it. Drugs considered to potentially have an effect on sexual function were antidepressants, antipsychotics, anxiolytics, benzodiazepines, beta-adrenergic antagonists, thiazide diuretics, some antacids (cimetidine and ranitidine), digoxin, methyldopa, non-steroidal anti-inflammatory agents, guanethidine, and progestogens. All participants in the study, having been informed in detail about its objectives, gave consent for their inclusion.
Of 280 patients recruited, 141 were assessed at the last study visit (visit 2), so that this was the sample used in the intent-to-treat analysis. A total of 135 were excluded because of personal reasons, withdrawal of consent, or failure to attend the second visit, and 4 were excluded because of protocol violation. The 141 patients who completed the study were analysed separately in two groups: group A (n = 79) included those who were not receiving AED treatment and started lamotrigine monotherapy; group B (n = 62) included patients treated with another AED who were changed to lamotrigine monotherapy either because of poor efficacy or adverse events to the previous AED. Within group B, 23 patients were receiving valproate, 18 carbamazepine, 9 phenytoin, 4 topiramate, 3 oxcarbazepine, 2 primidone, 2 clonazepam, and 1 phenobarbital. There was no difference in age among groups: mean 36.24 AE 14.51 years for group A and 38.17 AE 13.03 years for group B. Dosages of lamotrigine were the customary ones in clinical practice, both in monotherapy (incremental doses from 25 mg/day for 4 weeks, up to a maintenance dose of 100-200 mg/day), and in substitutive therapy. In the latter case, if the previous AED was carbama-zepine, phenytoin, primidone, or phenobarbital, the initial dose of lamotrigine was 50 mg/day for 2 weeks, followed by 100 mg/day for the following 2 weeks and 200 mg/day during Weeks 5 and 6. From Week 7 the dosage of lamotrigine was maintained and the withdrawal of the initial drug was completed over the following 4 weeks. When the original drug was valproate, the initial dose of lamotrigine was 12.5 mg/day (or 25 mg on alternate days) for the first 2 weeks, followed by 25 mg/day for the following 2 weeks and 50 mg, twice a day, during Weeks 5 and 6. Reduction of valproate began in Week 7, at a rate of 200-500 mg per week, in Week 8 the dosage of lamotrigine was increased to 150 mg/day, and finally, in Week 10 to 200 mg/ day. In patients treated with clonazepam, oxcarbazepine, or topiramate, lamotrigine was initiated in a similar schedule as in monotherapy, and the discontinuation of the prior AED completed in the following 4 weeks.
Measures
Patients were monitored over a period of 8 months, in which they were assessed on three occasions: baseline, visit 1 (4 months), and visit 2 (8 months). On each occasion they underwent a physical examination, in which their weight, height, and blood pressure were measured, and the frequency and type of their epileptic seizures recorded. Sexual function was assessed using the Changes in Sexual Functioning Questionnaire (CSFQ) both during baseline and at the final visit. The CSFQ was developed by Clayton et al.
14 to monitor changes in patients' sexual functioning, as a result of illness, medication, or both. A Spanish validation of this questionnaire was developed by Bobes et al. 15 The 14 items in the brief version of the questionnaire are grouped in five dimensions (desire/frequency, desire/interest, pleasure, arousal/excitement, and orgasm), and scored on a 5-point Likert-type scale, where 1 is the poorest rating (never, no enjoyment) and 5 the best (daily, a lot). The scale can be self-or physician-applied, and application time is usually 15-20 min. A total score is obtained, as well as scores for each of the five subscales or dimensions. Total score is obtained by adding up the scores in the 12 items making up the scale proper, plus those in 2 extra items (related to arousal and painful orgasms), so that total score can range from 14 to 70. Cut-off points proposed by the authors for differentiating between problems and absence of problems are desire/frequency, men 8, women 6; desire/interest, men 11, women 9; pleasure, 4 in both sexes; arousal/excitement, men 13, women 12; orgasm, men 13, women 11; and global sexual function, men 47, women 41.
In order to complete the information related to sexual function in patients with epilepsy, they were asked a series of specific questions: lack of sexual interest (never, rarely, sometimes, often, always); relation between lack of interest and the illness (not related, partially related, totally related); and relation between lack of interest and antiepileptic medication (not related, partially related, totally related).
Statistical analysis
An intent-to-treat data analysis was carried out, using, as a tool for interpreting lost values, the last-observation-carried-forward (LOCF) method, taking into account all the patients with baseline assessment and at least one more, even if they did not complete the full study period. Quantitative data were expressed through mean and standard deviation, and categorical variables were described by means of absolute and relative frequencies. For comparisons of the quantitative variables, we used the Student's t-test, and for comparisons between the categorical variables, the chi-squared test with Pearson modification. Between-group comparisons of the quantitative variables were made by means of covariance analysis (ANCOVA). The statistical significance criterion was set at p < 0.05. SAS system package, Version 8.02 (SAS Institute, Inc., Cary, NC, USA) was used for statistical analysis. Table 1 shows the most relevant demographic data of the patients participating in the study. In group A 54% patients were single, compared to a predominance of married (or cohabitational) patients in group B (56%). The anthropometric parameters at the beginning of the study (average weight 70.79 AE 12.21 kg; waist-hip ratio 0.83 AE 0.09) were within the normal range for this population, as were the blood pressure values (systolic pressure/diastolic pressure: 125.35 AE 15.73 mmHg/ 73.58 AE 9.53 mmHg). Tables 2 and 3 show the mean scores obtained in the CSFQ (mean score for the different dimensions and total score for the questionnaire) for the baseline visit and final visit (month 8), according to sex, and for patients who began their treatment with lamotrigine (group A, Table 2 ) and those in whom their AED was substituted by lamotrigine (group B, Table 3 ). Some questions (four or less in each case) were not answered by four patients in group A and three in group B, and these were excluded in some analysis (Tables 2 and 3 ). According to the cut-off points, problems of sexual function in all five dimensions were observed at baseline. In group A (patients who initiated therapy with lamotrigine in monotherapy), the total CSFQ score increased by 5.39 AE 6.95 points (CI 95%; 2.84-7.94; p < 0.05) in the subgroup of women (12% with respect to baseline) (Fig. 1) . In addition, this group also presented a significant improvement ( p < 0.05) in all the CSFQ dimensions (desire/frequency, desire/interest, pleasure, arousal/excitement, orgasm) ( Table 2) . On the contrary, in the men's subgroup total score increased by 1.12 AE 4.65 points (CI 95% ; 2.84-7.94) (2%), a difference that was not statistically significant ( p = 0.1306) (Fig. 1) ; however, significant differlamotrigine and sexual function 145 ences were observed in the pleasure dimension ( Table 2 ). In group B (patients in whom a previous AED was substituted by lamotrigine monotherapy), total CSFQ score increased, both in men (2.31 AE 6.52 points, CI 95%; À0.04 to 4.66) and in women (2.48 AE 7.06 points, CI 95%; À0.31 to 5.27), and to a similar extent in both sexes (5% in each), even though there were no statistically significant differences in either of the two subgroups ( Fig. 1 ; Table 3 ). Significant improvements were only observed ( p < 0.05) in some dimensions, such as pleasure and orgasm in men and desire/frequency in women. In the latter, a significant decrease in the score for the desire/interest dimension was observed ( Table 3 ). The cut-off point of the scale was only surpassed, at the end of the treatment, for differentiating the absence of problems in the women's subgroup for the desire/frequency dimension, in the two treatment groups.
Results
The difference in total CSFQ score between groups A and B was À0.17 points (CI 95%; À2.42 to 2.08) in men and 2.90 points (CI 95%; À0.49 to 6.29) in women, with no statistically significant differences in either case. Nevertheless, in the subgroup of women, significant differences were obtained in two dimensions of the CSFQ (arousal/ excitement, p = 0.0106; and orgasm, p = 0.0426), which showed higher scores in group A. On the other hand, no significant differences were found for changes in the CSFQ score in the analysis of the subgroups of patients who substituted carbamazepine or valproate by lamotrigine, either between them or with respect to group A. Table 4 shows the results for the three specific questions on sexual function and epilepsy that all participants were asked. Here, patients showed, though in an irregular way, a certain subjective lack of sexual interest (group A and group B scored in the 146
A. Gil-Nagel et al. range ''sometimes''-''always'' in proportions of 54 and 55%, respectively, at the beginning of the study), though the majority of the untreated patients did not associate this directly with the illness (70%)--in contrast to patients treated previously with an AED, 56% of whom linked this lack of interest, at least partially, to the epilepsy. In the final visit of the study, a significantly higher percentage of patients treated initially with lamotrigine believed that their lack of sexual interest was not caused by antiepileptic medication (88% in group A versus 73% in group B, p = 0.0461). The most marked differences in this respect were obtained in the subgroup of patients initially treated with carbamazepine (60%, p = 0.0164, compared to group A). Finally, a significant difference between group A and B was also found in the rate of patients that achieved complete seizure control (Fig. 2) . Seventynine percent of patients in group A were seizurefree at the end of the study, compared to 45% in group B ( p < 0.05).
Discussion
A combination of factors can explain the higher incidence of sexual function alterations in patients with epilepsy compared to the general population. [1] [2] [3] Social isolation, the social stigma associated with epilepsy, low self-esteem, and a higher incidence of depression among patients with epilepsy have a negative influence on the search for a partner, and may play a role in the appearance of sexual dysfunction. Physiological mechanisms also affect sexual function; epileptiform activity frequently originates or propagates to the limbic system, and some studies have found a higher prevalence of sexual dysfunction in patients with temporal lobe epilepsy compared to other epilepsies not involving the limbic system. 5 Moreover, improvement in sexual function has been observed in these patients when they attain complete seizure control after temporal lobectomy. 16 In addition, seizures and interictal activity may interfere the functioning of the hypothalamus-hypophysis-adrenal axis, giving rise to an anomalous secretion of sexual hormones. Indeed, some epileptic seizures provoke an increase in the secretion of prolactin, and excess of prolactin is known to cause diminished libido and impotence. 17 Similarly, increased levels of prolactin have been reported after generalized tonic-clonic seizures, 18 in relation to complex partial seizures in which the limbic system is activated, 19 and spontaneously during sleep in patients with partial epilepsy, without direct relation to the occurrence of seizures. 20 Hormonal changes and variations in the expression of neuronal receptors and ion channels through the life cycle influence the onset and remission of certain epilepsies such as some idiopathic generalized epilepsies and benign focal epilepsies of childhood. 21 Numerous studies demonstrate the epileptogenic effect of estrogens in experimental animals and humans, as well as the protective effect of progestogens against seizures, 22 mechanisms that explain in part the occurrence of catamenial epilepsy.
Finally, AEDs may also interfere with sexual function. 3 Drugs that induce the cytochrome P-450 enzyme system, such as carbamazepine, barbiturates, and hydantoines, can cause reduced libido lamotrigine and sexual function 147 and erectile dysfunction. The mechanisms of these side effects are not known; they could be related to a decrease in total testosterone levels due to its increased clearance by the enzymes of the P-450 complex, 3 a reduction of free testosterone levels caused by an increase in plasma concentration of globulins, to which sex hormones bind, 23 or an induction of aromatase, converting free testosterone to estradiol. 24, 25 In fact, in patients treated with carbamazepine and phenytoin total testosterone levels do not tend to be lower than those of the general population, but levels of freely circulating testosterone are indeed inferior. 26 Since lamotrigine does not induce or inhibit isoenzymes of the P-450 hepatic microsomal complex, it has been argued that this drug is less likely to cause sexual dysfunction. Evidence to support this claim is still scarce; Husain et al. report a series of three men with epilepsy in whom lamotrigine had a favourable effect on sexual dysfunction, including one case in which impotence resolved when the dose of carbamazepine was reduced and lamotrigine increased. 13 Furthermore, a recent study 27 showed that sexual function, bioactive testosterone levels, hormonal ratio (testosterone/estradiol), and gonadal efficiency (bioactive testosterone/luteinizing hormone) are better or higher in patients treated with lamotrigine than in those treated with enzymeinducing AEDs. In our study, the highest proportion of patients who associated lack of sexual interest with antiepileptic medication was observed in the subgroup of patients initially treated with carbamazepine. In addition, significant improvements were observed in some parameters of sexual functioning, such as pleasure and orgasm, in men treated with other AEDs when these were substituted by lamotrigine.
The CSFQ has been employed mostly in the field of mental health, 28, 29 and there are no published works on its application in patients with epilepsy. The present study contributes some data in this regard, showing that lamotrigine might have a positive effect on the sexual dysfunction presented by epileptic patients who start their treatment with this drug, and particularly in the case of women, as indicated by a statistically significant increase in CSFQ score. On the other hand, in the group of patients in which other AEDs were substituted by lamotrigine, while there was an increase in CSFQ score, it was not statistically significant. This difference among both groups could have several explanations. It is possible that a longer ''washout'' period is necessary in order to eliminate the deleterious effect of some AEDs on sexual function. In this sense, Herzog et al. 28 note that in patients with chronic epilepsy treated long-term with enzyme-inducing AEDs, the effect of these drugs on sexual hormones, once the therapy is interrupted, is not sufficiently established yet. Therefore, the period analyzed in this study may not have been long enough to obtain significant improvements in group B, particularly considering that the time required for full cessation of administration of the first AED is more than 2 months. While this possibility could explain the lack of effect on group B, it does not give any information on the positive effect observed in patients who receive lamotrigine monotherapy as the first treatment (group A); in this group the improvement in sexual function may be related to an improvement in seizure control, supported by the observation of a higher number of patients who became seizure-free in group A compared to group B. A second explanation could be an improvement in mood, other psychological factors, or quality of life as a result of an improvement in their clinical condition. Finally, these results may have been related to a moodstabilizing effect of lamotrigine. 30 In any case, because this is an open exploratory study, in which not all variables could be controlled, these results should be judged with caution, keeping in mind that a whole host of other factors (psychological, social, environmental, cultural, etc.) also intervene in sexual functioning, conditioning the response of each individual.
Conclusions
Concluding, and taking into account the limitations of this open study, we can state that an improvement in sexual function can be observed in some patients with epilepsy treated with lamotrigine, especially in women beginning their antiepileptic treatment with this drug. This can be the result of decreased seizures and side effects from other AEDs, improvement in quality of life, or a moodstabilizing effect of lamotrigine. In addition, it is possible that the CSFQ could be a useful tool to explore sexual function in both men and women with epilepsy. These results can serve to open the door to new comparative research, of a controlled nature, with larger samples and longer follow-up periods.
